Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline. Keep track of the Covid-19 Vaccination programme.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The incubation period of the novel Covid-19 coronavirus could be as long as 27 days, noted Reuters citing reports from Chinese provincial government.

In Hubei province, hard-hit by the coronavirus epidemic, an infected 70-year-old man did not exhibit Covid-19 symptoms until 27 days later.

On 24 January, the man had close contact with his infected sister, said Hubei government website. He had a fever on 20 February and received test confirmation the next day.

Currently, the incubation period of the coronavirus, SARS-CoV-2, is considered to be 14 days. Health authorities across countries are adopting a 14-day quarantine period, based on the World Health Organization guidelines.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A longer incubation period would impact the efforts focused on controlling the coronavirus spread.

Earlier this month, a study by Chinese researchers found that the incubation period can be up to 24 days. The median incubation period was found to be three days, with a range of zero to 24 days.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact